Correction to A prospective, randomized, multicenter, open-label trial comparing survival in subjects receiving peritoneal dialysis or conventional in-center hemodialysis

Abstract

Fan L, Yang X, Shen H, Chen M, Zhang H, Ni Z, et al. A prospective, randomized, multicenter, open-label trial comparing survival in subjects receiving peritoneal dialysis or conventional in-center hemodialysis. Med Adv. 2024; 2(2):112–22. https://doi.org/10.1002/med4.56.

In the ACKNOWLEDGMENTS section, the text “The authors thank Han Tao from Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University for English editing of the manuscript. The study was funded by Baxter Healthcare Corporation and designed by the sponsor and investigators. The funder had no role in study execution, data collection, data analysis, data interpretation, writing of the report, or the decision to submit the report for publication. Xueqing Yu has received grant/research support from the National Natural Science Foundation of China, Baxter, Wanbang Biopharmaceuticals, AstraZeneca, and GSK as well as consulting and lecture fees from Baxter, Wanbang Biopharmaceuticals, Fresenius, Fresenius Kabi, and Kyowa Kirin.” was incorrect. This should have read: “The authors thank Han Tao from Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University for English editing of the manuscript.”

In the CONFLICT OF INTEREST STATEMENT section, the text “The authors declare no conflicts of interest. Xueqing Yu, Jie Li, Chuanming Hao, Hongli Lin and Xia Zhou are Editorial Board Members/Editors-in-Chief for Medicine Advances but were not involved in the editorial review or decision to publish this article.” was incorrect. This should have read: “The study was funded by Baxter Healthcare Corporation and designed by the sponsor and investigators. The funder had no role in study execution, data collection, data analysis, data interpretation, writing of the report, or the decision to submit the report for publication. Xueqing Yu has received grant/research support from the National Natural Science Foundation of China, Baxter, Wanbang Biopharmaceuticals, AstraZeneca, and GSK as well as consulting and lecture fees from Baxter, Wanbang Biopharmaceuticals, Fresenius, Fresenius Kabi, and Kyowa Kirin. All other authors declare no relevant financial interests. Xueqing Yu, Jie Li, Chuanming Hao, Hongli Lin and Xia Zhou are Editorial Board Members/Editors-in-Chief for Medicine Advances but were not involved in the editorial review or decision to publish this article.”

In the 2.1 Study design, the detailed information about the Trial Registration. The missing information should have read as follows: “Registered at ClinicalTrials.gov with study number NCT01413074.”

We apologize for the error.